CClinicalTrials.gg
CompletedNCT00793767Updated May 29, 2009

Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

An interventional study of erythropoietin and placebo (saline) in Insulin Sensitivity, sponsored by Aarhus University Hospital. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-05-29.

Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Male
01

Study summary

Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Read the detailed description

Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

02

Conditions studied

  • Insulin Sensitivity

Keywords

  • Erythropoietin
  • human muscle tissue
  • insulin sensitivity
  • substrate metabolism
03

In context

Insulin Resistance

1,960 studies on the registry are indexed under Insulin Resistance; 306 are open to participants now.

This study's planned enrollment of 10 is below the median of 40 across 1,536 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

Aarhus University Hospital is the lead sponsor of 289 studies on the registry; 79 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy persons
  • Between 18 and 30 years
  • Normal weight (BMI: 18-25)

Exclusion criteria

Exclusion Criteria:

  • Severe heart disease (NYHA 3)
  • Uncontrolled hypertension
  • Previous cerebrovascular disease
  • Proliferative retinopathy
  • Diabetes
  • Musculo-skeletal diseases
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    placebo

    Drug: placebo (saline)

  • Experimental
    Erythropoietin

    acute administration of erythropoietin

    Drug: erythropoietin

Interventions

  • Drugerythropoietin

    bolus of 400 IU/kg

  • Drugplacebo (saline)

    i.v

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity

    Time frame: 4 and 6 hours post

Secondary outcomes

  1. Substrate metabolism

    Time frame: 4 and 6 hours post

07

Study locations

1 site
  • Medicinsk forsknings laboratorium
    Århus C, 8000, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00793767
Lead sponsor
Aarhus University Hospital
First posted
Nov 19, 2008
Start date
Jan 2009
Primary completion
Apr 2009
Last update
May 29, 2009

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion